New diabetes device data puts Merck's Januvia on notice

Merck's ($MRK) Januvia has seen its fair share of competition from generics makers and other diabetes challengers. But now, it could face a new rival on the scene--and it's a device. Boston-based Intarcia is touting data showing its tiny, implantable drug pump beat out Merck's best-seller in a head-to-head trial, reducing a type of hemoglobin linked to diabetes twice as much as Januvia. Story

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.